ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1435 National Cancer Institute Html en Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors.
testicular germ cell0.206027
treatment0.243869
germ cell tumors0.902772
stage0.204984
extracranial germ cell0.708761
ovarian germ cell0.212137
childhood extracranial germ0.398861
cancer0.399843
clinical trials0.265215
CLICK HERE
1484 National Cancer Institute Html en Pituitary Tumors Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of pituitary tumors.
treatment0.39139
diagnostic imaging choice0.347546
magnetic resonance imaging0.340677
pituitary tumors0.690926
pituitary adenomas0.92392
medical therapy exists.0.351515
pituitary lesion0.527537
transsphenoidal microsurgical approach0.343275
visual field0.394767
cell-type specific presentations0.354594
medical therapy0.38784
pituitary gland0.541344
gonadotroph adenomas0.356536
important clinical presentation0.355104
pituitary carcinomas0.731658
useful diagnostic tool0.338617
inactive pituitary adenomas0.650057
endocrine-inactive adenomas0.359468
pituitary adenoma0.802139
pituitary apoplexy0.612406
hormone-producing adenomas0.35841
Conventional radiation therapy0.361094
functional criteria0.339781
GH-receptor antagonists0.338498
adjunctive radiation therapy0.355238
MRI scan0.341418
effective medical treatment0.350208
pituitary disorders0.546502
appropriately selected patients0.348512
dopamine analogues0.357798
pituitary tumor0.625147
Sagittal T1-weighted images0.340975
patients0.403665
surgically high-risk patients0.358813
adjunctive medical therapy0.353866
Hormone-secreting pituitary carcinomas0.652967
significant suprasellar extension0.453203
safe surgical treatment0.370545
gross total tumor0.361957
surgical management0.338442
pituitary adenoma literature0.647061
pituitary neoplasms0.533177
postoperative radiation therapy0.355824
radiation therapy0.637553
somatostatin analogues0.402133
ergot-derived dopamine agonists0.339339
pituitary tumors.0.521498
CLICK HERE
1568 National Cancer Institute Html en Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors.
carcinoid tumor cells0.278965
metastatic GI carcinoid0.238039
treatment0.556764
cancer treatment0.277356
malignant tumor cells0.240006
general information0.281992
GI carcinoid tumors0.692008
Hormone therapy0.212489
Lung Cancer Treatment0.223918
NCI-supported cancer0.254433
cancer cells0.281516
stomach0.228344
hepatic artery0.21097
body0.300003
type0.211866
PDQ cancer information0.277061
clinical trial search0.358585
carcinoid tumor spreads0.266506
treatment clinical trials0.240478
recurrent GI carcinoid0.223511
National Cancer Institute0.243506
clinical trials0.834392
tumor cells0.308788
Carcinoid Tumors Treatment0.268829
cancer information summary0.243151
clinical trial0.501578
new treatment0.293328
Rectal Cancer Treatment0.224504
liver0.203338
gastrointestinal carcinoid tumor0.314953
patients0.237822
carcinoid heart syndrome0.215848
carcinoid tumor tissue0.264996
carcinoid syndrome0.334872
metastatic tumor0.206035
blood0.210445
cancer clinical trials0.359168
lymph nodes0.28707
carcinoid tumors0.943574
radiation therapy0.236209
internal radiation therapy0.21238
cancer0.673084
information0.294151
small intestine0.264836
gastrointestinal carcinoid tumors0.573326
Intestine Cancer Treatment0.236505
CLICK HERE
1577 National Cancer Institute Html en Retinoblastoma Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of retinoblastoma in children.
cancer treatment0.489298
body0.467706
type0.422666
PDQ cancer information0.456409
clinical trial search0.418893
retinoblastoma0.865388
retinoblastoma treatment centers0.451209
systemic chemotherapy0.574478
regular eye exams0.443823
clinical trials0.855386
recurrent intraocular retinoblastoma0.415908
high-dose chemotherapy0.465125
cancer information summary0.42823
clinical trial0.564195
patients0.408556
eye0.840016
radiation therapy0.862799
optic nerve0.459799
child0.430789
heritable form0.409154
treatment0.773723
bilateral intraocular retinoblastoma0.418197
heritable retinoblastoma0.466245
Nonheritable retinoblastoma0.41969
cancer cells0.573196
extraocular retinoblastoma0.479879
retinoblastoma cells0.416299
Intravitreal chemotherapy0.407999
treatment clinical trials0.426091
RB1 gene0.435629
National Cancer Institute0.44282
spinal cord0.437008
intraocular retinoblastoma0.468181
effects cancer treatment0.415229
new treatment0.441768
artery infusion chemotherapy0.538311
external-beam radiation therapy0.642309
recurrent extraocular retinoblastoma0.414269
ophthalmic artery infusion0.504849
metastatic retinoblastoma0.407008
trilateral retinoblastoma0.466869
bone marrow0.434989
cancer clinical trials0.449674
cavitary retinoblastoma0.436997
stem cell rescue0.535096
tumor0.495126
retinoblastoma spreads0.40533
internal radiation therapy0.438773
cancer0.972687
CLICK HERE
1678 National Cancer Institute Html en Communication in Cancer Care (PDQ®)–Health Professional Version Effective cancer communication between the health care team, cancer patients, and their family is important. Learn about communication skills that support a patient-centered practice and how to talk with adults and children about their diagnosis, prognosis, and transition to end-of-life care in this expert-reviewed summary.
female breast cancer0.57505
eligible patients0.564938
bad news0.743613
medical decision making0.58503
physicians0.592367
direct patient care0.564892
diverse cancer patients0.603459
clinical trials0.61877
communication0.630971
early-stage breast cancer0.592631
patients cultural beliefs0.582353
breast cancer experience0.564126
breast cancer treatment0.579002
breast cancer patients0.646574
patients0.906881
cancer patients0.64886
white patients0.564203
cancer diagnosis0.569139
health care costs0.565569
cancer patients report0.596785
decision making0.744128
breast cancer therapy0.566081
treatment decision making0.568266
older breast cancer0.566807
care0.590659
treatment0.626966
American oncology patients0.58299
study0.656108
patient communication preferences0.600601
cancer disclosure issues0.56732
African American patients0.584216
different information styles0.572854
Asian American women0.565505
patient decision making0.57769
black patients0.564183
younger patients0.563325
high information needs0.57343
health care0.579997
patient information style0.59028
older patients0.579527
initial cancer diagnosis0.562722
Cancer care0.562573
breast cancer0.780881
specific treatment information0.578443
patient satisfaction0.579033
information patients0.586119
treatment options0.585641
rural American patients0.584504
pessimistic information people0.566128
CLICK HERE
1740 National Cancer Institute Html en Hair Dyes and Cancer Risk A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.
female breast cancer0.364162
hair dye0.94208
hair dye products0.547022
hair dyes0.824788
Kupelnick B. Personal0.356107
Modern hair dyes0.445893
C. Personal hair0.381701
case-control study0.408793
bladder cancer0.729938
consumer exposure study0.34979
permanent hair dye0.484417
increased risk0.395633
case-control studies0.347772
bladder cancer risk0.47239
Montes-Martinez A. Personal0.354703
IARC Working Group0.350056
permanent hair dyes0.502056
MR. Bladder cancer0.389163
American Journal0.365295
temporary hair dyes0.442658
hair coloring products0.388447
currently marketed products0.354822
leukemia/small lymphocytic lymphoma0.349931
colorless dye0.417079
A. Bladder cancer0.391043
Cancer Epidemiology Biomarkers0.364493
International Journal0.379963
public health impact0.349406
black permanent dyes0.401612
color dyes0.375257
Personal permanent hair0.383955
United States0.383182
adult acute leukemia0.391088
non-Hodgkin lymphoma0.350907
conflicting results0.412706
bladder cancer study0.39321
earlier hair dyes0.42871
personal hair dye0.756765
studies0.389653
bladder-cancer risk0.359564
public health0.351318
dark-colored dyes0.399225
follicular lymphoma0.348182
recent dye formulations0.42394
aromatic amines0.360034
hair dye formulations0.474224
specific NHL subtypes0.351636
hair dye users0.497516
et al0.482744
CLICK HERE
2039 National Cancer Institute Html es Exámenes de detección del cáncer de piel (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar sistemáticamente el cáncer de piel.
skin cancer0.943888
pediatric melanoma0.526248
cutaneous melanoma0.524708
incidence estimate0.432333
pediatric melanoma mortality0.475024
Waldmann A0.448643
pruebas directas0.467472
accessed october0.431704
American Cancer Society0.752465
largo plazo0.427741
incidencia promedio0.427245
Am Acad Dermatol0.559713
Skin biopsy0.467836
CA Cancer0.436346
Preventive Services Task0.49324
Melanoma mortality following0.47412
Instituto Nacional0.477662
diagnosing melanoma0.465782
Melanoma Pathology Study0.472332
PDQ Exámenes0.446099
malignant skin tumors0.44617
Skin biopsy utilization0.44782
Estados Unidos0.486058
study comparing trends0.42068
Skin biopsy rates0.447638
JAMA Dermatol0.430327
US Preventive Services0.448303
melanoma incidence among0.478575
Nolte S0.427295
Rogers HW0.427126
consecuencias adversas0.434206
Gandini S0.430629
estudio screen0.45426
United States0.464438
Arch Dermatol0.504577
Cancer Facts0.476716
Weinstock MA0.509901
National Cancer Institute0.43929
Systematic skin0.44278
population-based screening intervention0.428982
Services Task Force0.491749
radiación uv0.425917
Dermatol Surg0.429711
systematic review0.43149
melanoma mortality0.579785
BMC Cancer0.438009
malignant melanoma0.574467
nonmelanoma skin cancer0.673873
Lott JP0.429356
CLICK HERE
3521 National Cancer Institute Html en NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Information about the NCI-MATCH precision medicine trial, in which patients with advanced solid tumors and lymphomas are assigned to treatment arms based on the molecular profiles of their disease.
NCI-MATCH trial0.544063
rare cancer0.541344
COMET study0.578429
genetic makeup0.540259
trial0.805751
clinical trial tracking0.631222
usual genomic testing0.608947
National Clinical Trials0.604691
MATCH protocol summary0.637152
treatment arms0.751732
clinical trials0.747821
newly enrolling patients0.642185
MATCH trial0.634351
health care professionals0.58508
cancer care0.539135
patients0.983397
cancer patients0.598511
tumor gene testing0.590848
ECOG-ACRIN Cancer Research0.612355
non-small cell lung0.606702
objective response rate0.771639
medicine cancer treatment0.706859
genomic sequencing0.623041
treatment arms address0.659842
gene sequencing lab0.599434
specific genetic change0.644953
laboratory method0.524995
Cancer Trials Support0.616424
potential MATCH participants0.636971
cancer cells0.549314
common genetic changes0.635293
Cancer Information Service0.610926
clinical trial.0.538943
genetic change0.741928
adult trial groups0.623508
health insurance company0.59001
enrolled patients0.575046
progression-free survival0.609538
specific genetic changes0.64881
NCI Community Oncology0.61311
particular genetic change0.630183
new tumor biopsy0.621774
genetic changes0.811113
MATCH treatment arm0.848463
Caris Life Sciences0.607515
NRG Oncology Group0.586136
advanced solid tumors0.669501
new clinical sites0.600949
CLICK HERE
3678 National Cancer Institute Html en NCI Outstanding Investigator Award Recipients Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.
Professor0.818386
cancer cell fate0.872486
tumor interstitial fluid0.811256
Institution0.848074
brain cancer stem0.81847
Salk Institute Cancer0.836669
cancer therapy0.800257
ccRCC tumor metabolism0.813028
cancer stem cell0.87789
Harvard Medical School0.902146
Institute Cancer Center0.918217
Mount Sinai Cancer0.82427
interactive research areas0.831532
new therapeutic targets0.831101
Tisch Cancer Institute0.836924
tumor suppressor functions0.808451
Cell Biology Laboratory0.802354
clinical cancer research0.915827
Hopkins University School0.800509
Medical Research0.805386
molecular mechanisms0.847735
human cancer metabolism0.844789
kidney cancer subtype0.813888
Cancer Research Program0.87416
mouse models0.817082
leukemia cell metabolism0.821118
Cancer Research Center0.897578
cancer cell metabolism0.867114
cancer cells0.87218
Stem Cell Biology0.799482
distinct cell types0.801724
Anderson Cancer Center0.828569
cancer research0.977431
Adolphus Pfeiffer Professor0.801659
HGG cancer cell0.848375
tumor suppressor gene0.80279
Center Research Institute0.861555
Title0.835958
Cancer Society Research0.870208
Stem Cell Research0.847258
Cell Biology0.815108
tumor microenvironment signals0.812505
Cancer Imaging Research0.895426
Cell Biology Department0.805035
acute lymphoblastic leukemia0.839865
Bakar Distinguished Professor0.809836
Wistar Institute Cancer0.864712
M. Temin Professor0.801808
tumor microenvironment0.889603
CLICK HERE
16845 National Cancer Institute Html en Masimo Corporation — Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance Developing a new therapeutic approach to triple negative breast cancer (TNBC) which is based on intracellular mechanical impact generated by plasmonic nanobubbles.
synergy0.336432
gold nanoparticles0.550066
liposome-encapsulated drugs0.504619
M.D.0.377619
intracellular gold nanoparticle0.766413
project team0.493532
chemotherapy0.340382
bubble generation threshold0.657269
short laser pulse0.734768
Ph.D.0.365843
TNBC0.333035
higher selectivity0.504113
goal0.33328
accumulation0.342776
absorption0.340473
negative breast cancer0.692185
nanomaterials0.340596
Co-Investigators0.334002
plasmonic nanobubbles0.543572
Principal Investigators0.516256
Resistance0.336765
radiotherapy0.347319
Masimo Corporation0.532528
Mechanical Drugs0.555482
EGFR-expressing cancer cells0.691288
Vladimir Torchilin0.519417
optical energy0.499453
Ph.D0.376534
larger gold clusters0.685801
mechanical impact0.858201
modalities0.337622
radiation oncology0.496973
Mien-Chie Hung0.526833
nanobubble-disrupted liposomes0.520675
Cancer Aggressiveness0.580782
normal cells0.511798
laser pulse0.92023
Gillenwater0.333958
Jack Phan0.537018
host cell0.497762
non-stationary vapor bubbles0.750751
gold nanoclusters0.536739
new therapeutic approach0.68193
Nie0.367583
Dmitri Lapotko0.533767
molecular / cell0.487681
low-energy laser pulse0.711917
intracellular mechanical impact0.751573
cancer biology0.50282
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.